专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022251450A1 LESIONAL DOSIMETRY FOR TARGETED RADIOTHERAPY OF CANCER CROSS-REFERENCE TO RELATED APPLICATIONS 审中-公开
公开(公告)号：WO2022251450A1
公开(公告)日：2022-12-01
申请号：PCT/US2022/031066
申请日：2022-05-26
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： LARSON, Steven M. , MAUGUEN, Audrey , HUMM, John L. , GREWAL, Ravinder K. , HO, Alan L.
IPC分类号： G06T7/10 , A61B6/03 , A61N5/10
摘要： The present disclosure provides lesional dosimetry methods for predicting the radioisotope activity required to deliver a therapeutic dose of radiation to induce an anti-tumor response in tumor lesions in a subject in need thereof. Specifically implemented is a computer-implemented dosimetry method comprising: detecting, in a single-time-point medical image of a patient, for each cancerous lesion of the patient, an indicator of a surrogate of a radiotherapeutic compound. The medical images captured within a predetermined time range following administration of the surrogate to the patient. Using each indicator, determining an uptake metric corresponding to uptake of the surrogate by each corresponding cancerous lesion. Generating, based on the predetermined time range and the uptake metric, using a dosimetry biomarker based on uptake of the surrogate by subjects in a cohort of subjects, a radiation dose prediction for administration of the radiotherapeutic compound to the patient. Resulting in providing the radiation dose prediction for subsequent use by a healthcare professional in determining a treatment protocol for treating the cancerous lesions of the patient using the radiotherapeutic compound.

2. 发明申请

WO2016191186A1 SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING 审中-公开
标题翻译：用于确定肿瘤定位最佳患者特异性抗体剂量的系统和方法
公开(公告)号：WO2016191186A1
公开(公告)日：2016-12-01
申请号：PCT/US2016/033217
申请日：2016-05-19
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： ZANZONICO, Pat B. , CHEAL, Sarah M. , LARSON, Steven M. , OSBORNE, Joseph Reginald , FUNG, Edward Komin , ULMERT, David
IPC分类号： A61K39/395
CPC分类号： A61K51/1045 , A61K51/1057 , A61K51/1063 , A61K51/1093 , A61K51/1096 , A61K2039/505 , A61K2039/545 , C07K16/3046 , C07K2317/24 , G16H50/50
摘要： The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.
摘要翻译：本公开描述了使用PET衍生数据的非线性区室模型，以患者特定的基础来预测载运抗体（例如，huA33）的最佳治疗剂量，例如放射性标记抗体，抗原占用率，住院时间正常和恶性组织，以及癌细胞与正常组织（例如结肠直肠癌与正常结肠组织）治疗指数。此外，非线性区室模型可以很容易地应用于旨在进一步改善RIT治疗指标的多步靶向（MST）策略的开发。

3. 发明申请

WO2020055929A1 BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE 审中-公开
公开(公告)号：WO2020055929A1
公开(公告)日：2020-03-19
申请号：PCT/US2019/050490
申请日：2019-09-10
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： PILLARSETTY, Naga Vara Kishore , LARSON, Steven M. , LEE, Sang-Gyu
IPC分类号： A61K9/00 , A61K9/127 , A61P35/02
摘要： Described herein are compositions comprising liposome-based nanocarriers and associated drugs that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The compositions also selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver), while minimizing delivery to the tumor in order to deliver drugs that prevent bone marrow suppression (BMS) or aid recovery post exposure to radiation. There are a wide range of scenarios for which such radiation protection is useful, e.g., protection from radiation delivered as part of cancer therapy, radiation from weapons, radiation from materials at a nuclear power plant or nuclear waste site, natural radiation in outer space (e.g., for astronauts), and the like. The described compositions are stable for prolonged periods of time, in some cases over a year in a kit formulation.

4. 发明申请

WO2019010299A1 DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY 审中-公开
公开(公告)号：WO2019010299A1
公开(公告)日：2019-01-10
申请号：PCT/US2018/040911
申请日：2018-07-05
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： CHEAL, Sarah M. , MCDEVITT, Michael , OUERFELLI, Ouathek , LARSON, Steven M. , YANG, Guangbin
IPC分类号： A61K51/04 , C07D403/02 , C07D403/12 , C07D403/14
摘要： The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225 Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

5. 发明申请

WO2021041896A1 NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS 审中-公开
公开(公告)号：WO2021041896A1
公开(公告)日：2021-03-04
申请号：PCT/US2020/048524
申请日：2020-08-28
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： PILLARSETTY, Naga Vara Kishore , KALIDINDI, Teja Muralidhar , LEE, Sang-Gyu , LARSON, Steven M. , LEWIS, Jason S. , LYASHCHENKO, Serge , BURNAZI, Eva
IPC分类号： A61K31/58 , C07J43/00 , C12Q1/68
摘要： The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.

6. 发明申请

WO2016130539A2 MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF 审中-公开
标题翻译：人类A33抗原和DOTA金属复合物具有亲和力的多特异性抗体及其用途
公开(公告)号：WO2016130539A2
公开(公告)日：2016-08-18
申请号：PCT/US2016/017141
申请日：2016-02-09
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： CHEAL, Sarah M. , XU, Hong , LARSON, Steven M. , CHEUNG, Nai-Kong
IPC分类号： A61K39/395 , A61K31/555
CPC分类号： A61K45/06 , A61K39/39575 , A61K47/6879 , A61K47/6897 , A61K51/0482 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2319/33
摘要： Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
摘要翻译：本文描述了结合A33和1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的多特异性结合剂。本文还提供了使用多特异性结合剂或其组合物用于检测，预防和/或治疗性治疗以A33糖蛋白抗原特别是结直肠癌表达为特征的疾病的方法。

7. 发明申请

WO2022081443A2 ANTI-PSMA ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2022081443A2
公开(公告)日：2022-04-21
申请号：PCT/US2021/054343
申请日：2021-10-11
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： CHEUNG, Nai-Kong V. , LIN, Tsung-Yi , LARSON, Steven M.
IPC分类号： A61K38/02 , C07K16/28 , C07K16/30 , A61K47/54 , A61K2039/505 , A61P35/00 , C07K16/2809 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present disclosure relates generally to immunoglobulin-related compositions (e.g antibodies or antigen binding fragments thereof) that can bind to the PSMA protein. The antibodies of the present technology are useful in methods for detecting and treating a PSMA- associated pathology in a subject in need thereof.

8. 发明申请

WO2021046331A1 ANTI-STEAP1 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2021046331A1
公开(公告)日：2021-03-11
申请号：PCT/US2020/049377
申请日：2020-09-04
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： CHEUNG, Nai-Kong V. , LIN, Tsung-Yi , LARSON, Steven M.
IPC分类号： C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40
摘要： The present technology relates generally to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that specifically bind STEAP1 protein and uses of the same. In particular, the present technology relates to the preparation of STEAP1 binding antibodies and their use in detecting and treating STEAP1 -associated cancers.

9. 发明申请

WO2017155948A1 BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE 审中-公开
标题翻译：骨髓，内皮细胞系统和/或淋巴节点靶向放射性脂质体以及它们的诊断和治疗方法
公开(公告)号：WO2017155948A1
公开(公告)日：2017-09-14
申请号：PCT/US2017/021092
申请日：2017-03-07
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： PILLARSETTY, Naga Vara Kishore , LARSON, Steven M. , LEE, Sang-gyu
IPC分类号： A61K47/69 , A61P35/00
摘要： Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver). Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure on the individual.
摘要翻译：本文描述的是与常规全身递送相比，选择性靶向骨髓的脂质体基纳米载体，使肿瘤递送最小化并且在骨髓中维持高药物浓度。还可以调整基于脂质体的纳米载体的组成以选择性地靶向淋巴结和其他网状内皮系统器官（例如，脾脏，例如肝脏）。本文还描述了使用所描述的基于脂质体的纳米载体成像和绘制骨髓和/或其他网状内皮系统器官的方法。这些方法通过PET提供高分辨率的非侵入性和定量成像，与传统的成像/跟踪方法相比具有优势。此外，在某些实施方案中，基于脂质体的载体用于稳定辐射防护剂/自由基清除剂并将其递送至骨髓，由此保护骨髓免受随后的辐射暴露，由此限制辐射暴露对个体的不利影响。

10. 发明公开

EP4025609A1 ANTI-STEAP1 ANTIBODIES AND USES THEREOF 审中-实审
公开(公告)号：EP4025609A1
公开(公告)日：2022-07-13
申请号：EP20860238.3
申请日：2020-09-04
申请人： Memorial Sloan Kettering Cancer Center
发明人： CHEUNG, Nai-Kong V. , LIN, Tsung-Yi , LARSON, Steven M.
IPC分类号： C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式